Masitinib is used to treat the purposes of patients with amyotrophic lateral sclerosis subgroup
US2017119760A1
Use of masitinib for the treatment of progressive supranuclear palsy
US2018311236A1
Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
CA3000894A1
Treatment of severe systemic mastocytosis with masitinib
US2017020867A1
Use of masitinib for the treatment of crohn's disease
US2016175302A1
Masitinib for treating gastric cancer
WO2016096933A1
Masitinib combination for use in treating breast cancer
US2016089368A1
Treatment of mastocytosis with masitinib
US2016128999A1
Masitinib for treating hepatic cancer
WO2016071511A1
Treatment of mast cell activation syndrome (mcas) with masitinib
US2016022671A1
Treatment of mastocytosis with masitinib
EP3144307A1
Novel oxazole derivatives that inhibit syk
AU2015238546A1
Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors
EP3053920A1
Compounds with anti-tumoral activity
TW201605449A
Use of masitinib for treatment of colorectal cancer
US2016263110A1
Use of masitinib for treatment of amyotrophic lateral sclerosis
TW201514311A
Method for determining the prognosis of pancreatic cancer
TW201534597A
Benzimidazole derivatives as selective proteine kinase inhibitors
WO2015185958A1
Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
EP2922572A1
Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
